The purpose of this study is to establish the efficacy of R89674 0.25% ophthalmic solution compared with placebo in alleviating the signs and symptoms of conjunctival allergen challenge-induced allergic conjunctivitis
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
150
Unnamed facility
Indianapolis, Indiana, United States
Unnamed facility
Lewiston, Maine, United States
Unnamed facility
Rochester, New York, United States
Unnamed facility
Charlotte, North Carolina, United States
Unnamed facility
Ocular itching and conjunctival redness post challenge
Ciliary and episcieral redness; chemosis; lid swelling; tearing; ocular mucous discharge; and nasal symptoms. All measured postchallenge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Philadelphia, Pennsylvania, United States